The Institute for Clinical and Economic Review (ICER) on Thursday, Jan. 23, released a draft evidence report assessing treatments for sickle cell disease, including Novartis’ Adakveo, Global Blood Therapeutics’ Oxbryta and Emmaus Life Sciences’ Endari.
According to a press release, the report is open to public feedback until 5 p.m. EST Feb. 20.
“While assessing the value of these treatments, policymakers will need to consider the substantial lifelong burden associated with sickle cell disease, as well as the potential for these treatments to reduce the disparity in life expectancy between black and white Americans,” ICER said in the release.
To read the draft report on ICER’s website, click here.
Click here to read the full press release.